RE:RE:Today s Financing It says "affiliate" of MAM. Is there a reason no name or is this just some vehicle for the deal? MAM are not biotech specialists so unless the affiliate is then maybe it's unlikely the specifics of the oncology program aren't all that important to the deal.
Wino115 wrote:
This deal would make zero sense if you did not see some factual evidence that the probability of your oncology platform being something of value is better than a 50/50 shot. While they still have $30mil or so cash on the balance sheet, don't forget there is an issued and approved ATM so if their backs against the wall they can easily payoff the small remaining convert balance and have a bit of cash in the bank.
But a conservative Board allowing a company to do this without clearer insight that a main future asset is trending in the right direction would be very bad oversight of management.
one thing todays reaction proves, no one was selling because of the convert due in a year like we think. We are assuming a rational market for the share and it has reacted to the unclear capital situation and delayed trial. While the latter could be part, the former wasn't. The market is more driven by pure illiquidity, ill-information and apathy. It's not as smart as we think.
it also shows the small cap problem -when you lose a shareholder through apathy they never come back. They constantly need to drum up new investors who believe they investment case yet the efforts have been middling if they are honest. First step-- build a solid thesis if you see POC around Th1902. Make it the game changer if it is.
palinc2000 wrote: Today s financing has really just TWO postives IMO.
1-It pushes back the dark cloud of the darn Convert due in less than 12 months .The Convert was an unsecured loan bearing interest at 5.75% and is being repaid by a Secured Term LOan bearing interest at more than 11% .....So more than half of the term loan is used to retire the Convert ,However only 40 million of the term loan is made available at Closing without any conditions .The balance of the term loan will ne made available in 3 tranches upon THTX achieving undisclosed milestones ,,,,,Not knowing what the milestones are its hard to say if they are easily achievable ...(based on sales %% based on stock issues?,based on cash flow ? I dontt hink that clinical results are part of the milestones
SO today the Company is getting oxigen to push back the June 30 2023 Convert darl Cloud....
I am not sure if the company will disclose the milestones which would trigger the disbursements of the tranches,,,,I expect they will after Closing
So a sigh of relief but for now it is just a refinancing of PART of the Convert (Convert 57 million new cash at Closing 40 million)
2-The second positive is that it should be easier to attract new equity investors to fund the R&D since the company will not have the risk of defauting on the Convert in the short term
SO I think we will see some new money rather quickly from partnerships .collaboration agreements,and possibly equity
The market will react favorably once the NEW money comes in